Morgan Stanley’s Sanofi Contingent Value Rights GCVRZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-9,412
| Closed | -$8K | – | 6973 |
|
|
2019
Q4 | $8K | Sell |
9,412
-19,117
| -67% | -$14.7K | ﹤0.01% | 6335 |
|
|
2019
Q3 | $16K | Buy |
28,529
+78
| +0.3% | +$42 | ﹤0.01% | 6081 |
|
|
2019
Q2 | $15K | Buy |
28,451
+22
| +0.1% | +$11 | ﹤0.01% | 6034 |
|
|
2019
Q1 | $13K | Sell |
28,429
-3,929
| -12% | -$1.83K | ﹤0.01% | 6131 |
|
|
2018
Q4 | $15K | Sell |
32,358
-651
| -2% | -$323 | ﹤0.01% | 6087 |
|
|
2018
Q3 | $17K | Sell |
33,009
-1,052
| -3% | -$564 | ﹤0.01% | 6195 |
|
|
2018
Q2 | $17K | Sell |
34,061
-451
| -1% | -$210 | ﹤0.01% | 6193 |
|
|
2018
Q1 | $14K | Buy |
34,512
+649
| +2% | +$261 | ﹤0.01% | 6209 |
|
|
2017
Q4 | $13K | Buy |
33,863
+478
| +1% | +$181 | ﹤0.01% | 6182 |
|
|
2017
Q3 | $12K | Sell |
33,385
-1,304
| -4% | -$483 | ﹤0.01% | 6147 |
|
|
2017
Q2 | $12K | Buy |
34,689
+4,550
| +15% | +$1.86K | ﹤0.01% | 6208 |
|
|
2017
Q1 | $14K | Buy |
30,139
+217
| +0.7% | +$95 | ﹤0.01% | 6176 |
|
|
2016
Q4 | $11K | Sell |
29,922
-704
| -2% | -$238 | ﹤0.01% | 6150 |
|
|
2016
Q3 | $8K | Buy |
30,626
+2,370
| +8% | +$600 | ﹤0.01% | 6172 |
|
|
2016
Q2 | $8K | Sell |
28,256
-2,208
| -7% | -$380 | ﹤0.01% | 6134 |
|
|
2016
Q1 | $3K | Sell |
30,464
-12,461
| -29% | -$1.35K | ﹤0.01% | 6387 |
|
|
2015
Q4 | $4K | Sell |
42,925
-938
| -2% | -$132 | ﹤0.01% | 6445 |
|
|
2015
Q3 | $9K | Sell |
43,863
-268
| -0.6% | -$91 | ﹤0.01% | 6282 |
|
|
2015
Q2 | $31K | Sell |
44,131
-675
| -2% | -$467 | ﹤0.01% | 6020 |
|
|
2015
Q1 | $30K | Buy |
44,806
+8,987
| +25% | +$6.29K | ﹤0.01% | 5963 |
|
|
2014
Q4 | $28K | Sell |
35,819
-21,819
| -38% | -$14.9K | ﹤0.01% | 5980 |
|
|
2014
Q3 | $26K | Sell |
57,638
-232
| -0.4% | -$113 | ﹤0.01% | 5931 |
|
|
2014
Q2 | $30K | Sell |
57,870
-119,167
| -67% | -$57.6K | ﹤0.01% | 5926 |
|
|
2014
Q1 | $54K | Buy |
177,037
+138,468
| +359% | +$51.5K | ﹤0.01% | 5680 |
|
|
2013
Q4 | $13K | Sell |
38,569
-978,733
| -96% | -$1.18M | ﹤0.01% | 5993 |
|
|
2013
Q3 | $2.06M | Buy |
1,017,302
+902
| +0.1% | +$1.72K | ﹤0.01% | 3191 |
|
|
2013
Q2 | $1.93M | Buy |
+1,016,400
| New | +$1.79M | ﹤0.01% | 3181 |
|
Morgan Stanley's GCVRZ Position: Q1 2020 in Review
Morgan Stanley sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2020, closing a stake of 9,412 shares — an estimated $8K sold.
Morgan Stanley first reported a position in GCVRZ in Q2 2013 and held it in 27 quarters. The position peaked at $2.06M in Q3 2013. 2 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2020.
- Morgan Stanley reported no remaining Sanofi Contingent Value Rights position as of Q1 2020 after selling out during the quarter.
- Morgan Stanley sold 9,412 Sanofi Contingent Value Rights shares in Q1 2020, an estimated $8K.
- Morgan Stanley first reported a position in Sanofi Contingent Value Rights in Q2 2013 and held it in 27 quarters.
- Morgan Stanley's Sanofi Contingent Value Rights position peaked at $2.06M in Q3 2013.
- 2 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2020.
Based on Morgan Stanley's 13F filing for Q1 2020, filed 15 May 2020.